Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Assets (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Non-Current Assets readings, the most recent being $190000.0 for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 95.56% to $190000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 million, a 73.88% decrease, with the full-year FY2025 number at $190000.0, down 95.56% from a year prior.
  • Non-Current Assets hit $190000.0 in Q4 2025 for Arcadia Biosciences, down from $197000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $19.9 million in Q2 2021 to a low of $190000.0 in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $4.4 million (2022), compared with a mean of $5.8 million.
  • Biggest five-year swings in Non-Current Assets: soared 70.19% in 2021 and later crashed 95.76% in 2025.
  • Arcadia Biosciences' Non-Current Assets stood at $8.5 million in 2021, then plummeted by 58.69% to $3.5 million in 2022, then soared by 34.31% to $4.7 million in 2023, then dropped by 9.68% to $4.3 million in 2024, then crashed by 95.56% to $190000.0 in 2025.
  • The last three reported values for Non-Current Assets were $190000.0 (Q4 2025), $197000.0 (Q3 2025), and $209000.0 (Q2 2025) per Business Quant data.